Monitor SITC abstract release on November 3, 2026, and the poster presentation on November 6, 2026, for potential new efficacy or safety data. The prior ASCO data showed encouraging signals in a heavily pre-treated melanoma population, but no new data are disclosed here. The activist stake (Lantheus 13D/A filed Sep 4) adds a layer of strategic interest.
Price Chart
Executive Summary
Perspective Therapeutics announced that data from its lapemelanotide zapixetar ([²¹²Pb]VMT01) program for metastatic melanoma have been accepted for presentation at the SITC 41st Annual Meeting in November 2026. The abstract (Number 571) will be presented as a poster on November 6, 2026, and SITC will release further details on November 3, 2026. This is a routine clinical milestone with no new data disclosed in the press release.
Key Facts
- Data from the [²¹²Pb]VMT01 program accepted for poster presentation at SITC 41st Annual Meeting (Nov 4-8, 2026, Phoenix, AZ).
- Abstract Number 571; presentation date: Friday, Nov. 6, 2026.
- SITC plans to release further details for regular abstracts on November 3, 2026.
- Prior interim analysis (data cut-off March 25, 2026) presented at ASCO 2026 showed 2 responders out of 7 in the 3.0 mCi monotherapy cohort, 86% stable disease or partial response, and no DLTs or Grade 4/5 TEAEs.
- Cross-filing context: Lantheus Holdings filed a Schedule 13D/A on September 4, 2026, indicating activist stake near this press release.
Financial Impact
No financial data or guidance provided in the press release.
Risk Factors
- Clinical data may not replicate prior positive signals from the ASCO interim analysis.
- Competition from other radiopharmaceutical and immunotherapy approaches in melanoma.
- Regulatory and development risks typical of early-stage radiopharmaceutical programs.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373912 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers